Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study

BACKGROUND: In pulmonary arterial hypertension (PAH), combination therapy is an important treatment strategy. Although randomized controlled trial data are available to support the combination of two therapies, data regarding triple combination therapy are few. OBJECTIVE: The phase III GRIPHON trial...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Cardiovasc Drugs
Main Authors: Coghlan, J. Gerry, Channick, Richard, Chin, Kelly, Di Scala, Lilla, Galiè, Nazzareno, Ghofrani, Hossein-Ardeschir, Hoeper, Marius M., Lang, Irene M., McLaughlin, Vallerie, Preiss, Ralph, Rubin, Lewis J., Simonneau, Gérald, Sitbon, Olivier, Tapson, Victor F., Gaine, Sean
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2018
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5772136/
https://ncbi.nlm.nih.gov/pubmed/29307087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40256-017-0262-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados